Condition: Myeloproliferative Neoplasms · Sponsor: Incyte Corporation
This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.
This description comes directly from the study's public registry record.
Incyte Corporation Call Center (US) · 1.855.463.3463 · medinfo@incyte.com
Incyte Corporation Call Center (ex-US) · +800 00027423 · eumedinfo@incyte.com
Always discuss trial participation with your own doctor first.
| Royal Brisbane and Women'S Hospital | Herston, Queensland, Australia | Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| Peter Maccallum Cancer Centre | Melbourne, Victoria, Australia | Recruiting |
| The Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Princess Margaret Cancer Center | Toronto, Ontario, Canada | Recruiting |
| Hopital Maisonneuve-Rosemont, Montreal, Qc | Montreal, Quebec, Canada | Recruiting |
| Odense University Hospital | Odense C, Denmark | Withdrawn |
| Sjaellands Universitetshospital | Roskilde, Denmark | Recruiting |
| Vejle Hospital | Vejle, Denmark | Recruiting |
| Institut Bergonie | Bordeaux, France | Recruiting |
| Chu Nimes | Nîmes, France | Recruiting |
| Hospital Saint Louis | Paris, France | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05936359